Neoantigen × AI
Daily research signal
№43Brief

Intismeran phase 3 walkthrough maps industrialized melanoma vaccine personalization

Today's items bracket the neoantigen field's near- and long-term: phase 3 execution of an individualized mRNA therapy in melanoma — plus a headline relapse-risk figure still awaiting a primary source — alongside two platform-level advances in antigen validation and delivery.Targeted OncologyThe New York SunPubMednews

The intismeran coverage is a clear walkthrough of what industrialized personalization actually requires, from tumor/normal NGS to computational ranking to per-patient mRNA synthesis.Targeted Oncology The TCR-pMHC methods guide and MIT's density-tunable phage nanofiber target the field's two standing bottlenecks: selecting antigens T cells will actually recognize, and displaying them in a format that works.PubMednewsInteresting Engineering

5new stories
AI / MethodstodayNew

Employing Protein Language Models to Predict TCR-Peptide-MHC Binding: A Comprehensive Methods Guide.

A new methods chapter offers a practical guide to TCR–peptide–MHC binding prediction — the computational layer that determines whether a predicted neoantigen is actually recognized by T cells. It covers protein language model-era tools including TCR-ESM, NetTCR-2.2, ERGO-II, pMTnet, and ATM-TCR, plus ESM-2-, tcrLM-, and graph neural network-based approaches, with protocols for data preparation, execution, interpretation, and tool selection by research objective. For vaccine developers, this is a benchmarking reference for the immunogenicity-prediction step downstream of every neoantigen selection pipeline.

europepmc · today · Yadav S, Vora DS, Dhanjal JK.

04

01
ClinicaltodayNew

Personalized Cancer Vaccine Cuts Melanoma Relapse Risk by 42 Percent in Landmark Trial - The New York Sun

The New York Sun reports a personalized cancer vaccine cutting melanoma relapse risk by 42% in what it calls a landmark trial. The item is headline-only — no sponsor, trial registration, or statistical detail is provided — so treat the figure as unverified pending the underlying data release. It runs alongside today's detailed intismeran/INTerpath-001 coverage; confirm from the primary source which program the number belongs to before acting on it.

news · today · The New York Sun
02
AI / MethodstodayNew

Nanoscale particle shows potential as customizable delivery vehicle for personalized cancer vaccines - News-Medical

MIT's Belcher lab (Koch Institute) published a delivery platform built on modified M13 bacteriophage nanofibers coated with cancer antigens at controlled density; in mice, the density-tuned particles prevented colon tumor development. The design is modular — antigens can be swapped on demand — which maps directly onto the personalized use case where each patient's antigen list differs. Published in Advanced Healthcare Materials with senior author Angela Belcher and research scientist Shengnan Huang; this is preclinical platform work, not a clinical signal.

news · today · News-Medical
03
AI / MethodstodayNew

MIT's viral nanofiber could help create personalized cancer vaccines - Interesting Engineering

A second account of the same MIT M13 nanofiber platform adds the quantitative detail: antigen display density was tuned across a 6%–70% range, and the higher-density formulation reduced the likelihood of both melanoma and colon tumor development in mice. The takeaway is that display density — a formulation variable rather than an antigen-selection one — materially changes vaccine performance. Coverage remains preclinical, with no human testing or manufacturing path described.

news · today · Interesting Engineering
04
ClinicalyesterdayNew

Long Explains the Process of Individualizing Neoantigen Therapy in Melanoma - Targeted Oncology

At the 2026 ESMO Congress, Georgina Long detailed how intismeran autogene is built per patient in the phase 3 INTerpath-001 trial (NCT05933577) in resectable melanoma: tumor-vs-normal NGS to identify private mutations, computational ranking by clonality, expression, and MHC class I/II profile, then encoding up to 34 top-ranked neoantigens into a single synthesized mRNA. She also addressed the trial's global scale and the practical steps still needed before the approach reaches patients. For investors, the interview underscores that the differentiator in this category is the biopsy-to-dosed-product pipeline, not the vaccine concept itself.

news · yesterday · Targeted Oncology